| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 2,6000% | ₹2050% | 1,300 | ₹0.05-50% | 48,7500% |
| - | - | 1,320 | ₹0.150% | 6,5000% |
| - | - | 1,340 | ₹0.050% | 56,5500% |
| 6500% | ₹135.650% | 1,360 | ₹0.05-83.33% | 26,000-18.36% |
| 00% | ₹101.50% | 1,380 | ₹0.05-50% | 28,600-8.33% |
| 17,5503.84% | ₹104.45-0.52% | 1,400 | ₹0.10% | 81,250-20.38% |
| 4,5500% | ₹66.10% | 1,420 | ₹0.05-80% | 80,600-6.06% |
| 11,7000% | ₹62.5-4.79% | 1,440 | ₹0.05-80% | 1,63,800-25.66% |
| 17,550-3.57% | ₹41.75-5.11% | 1,460 | ₹0.05-87.5% | 1,44,300-32.31% |
| 1,10,500-8.60% | ₹3029.87% | 1,480 | ₹0.1-80% | 3,02,250-32.51% |
| 6,31,150-21.31% | ₹0.05-98.96% | 1,500 | ₹0.05-97.87% | 2,43,750-40.85% |
| 4,70,600-26.42% | ₹0.05-95.45% | 1,520 | ₹23.8533.24% | 66,950-33.54% |
| 6,76,650-10.64% | ₹0.05-83.33% | 1,540 | ₹36.3-2.94% | 26,650-4.65% |
| 2,82,750-22.45% | ₹0.05-83.33% | 1,560 | ₹58.655.67% | 39,650-11.59% |
| 1,83,300-20.33% | ₹0.1-50% | 1,580 | ₹73.55-12.44% | 7,800-25% |
| 2,39,850-21.82% | ₹0.05-66.66% | 1,600 | ₹96-8.48% | 20,800-3.03% |
| 60,450-34.96% | ₹0.05-66.66% | 1,620 | ₹114.85-4.68% | 2,6000% |
| 35,100-25% | ₹0.05-75% | 1,640 | ₹158.450% | 4,5500% |
| 50,700-26.41% | ₹0.05-50% | 1,660 | ₹156.70% | 6500% |
| 24,700-36.66% | ₹0.05-50% | 1,680 | - | - |
| 74,100-5.78% | ₹0.05-50% | 1,700 | ₹210.5-0.23% | 2,6000% |
| 1,78,7500% | ₹0.050% | 1,720 | - | - |
| 3,900-68.42% | ₹0.050% | 1,760 | - | - |
| 74,1000% | ₹0.10% | 1,800 | ₹2980% | 1,3000% |
For the quarter, net profit soared 49% on-year to ₹1,570 crore, on the back of higher revenue and better operating efficiency.
According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market
The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.
For the first nine months of FY25, Cipla's EBITDA margin stood at 26.9%, already above its full-year guidance of 24.5% to 25.5%.
Cipla reported a net profit of ₹1,303 crore, marking a 15% increase compared to the same period last year.
The VAI designation now clears the way for significant specialised launches, such as the Abraxane generic.
The company is now able to pursue important speciality medicine launches because to its VAI classification.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Tata Power, Biocon, etc.
Cipla's total research and development expenditure for the quarter reached ₹385 Crore, representing 5.5% of total sales and reflecting a 2% increase year-on-year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
